{"id":"r-tpa","safety":{"commonSideEffects":[{"rate":"0.6–6%","effect":"Bleeding (intracranial hemorrhage)"},{"rate":null,"effect":"Reperfusion arrhythmias"},{"rate":null,"effect":"Hypotension"},{"rate":"<1%","effect":"Allergic reactions"}]},"_chembl":{"chemblId":"CHEMBL454475","moleculeType":"Small molecule","molecularWeight":"843.20"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"r-tPA is a serine protease that binds to fibrin in thrombi and catalyzes the conversion of plasminogen to plasmin, which degrades the fibrin matrix of blood clots. This fibrinolytic action dissolves thrombotic occlusions and restores perfusion in occluded vessels. It is used acutely to restore blood flow in thrombotic events such as ischemic stroke and myocardial infarction.","oneSentence":"r-tPA is a recombinant tissue plasminogen activator that converts plasminogen to plasmin, breaking down fibrin clots to restore blood flow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:04.389Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"},{"name":"Acute myocardial infarction"},{"name":"Pulmonary embolism"}]},"trialDetails":[{"nctId":"NCT06184321","phase":"EARLY_PHASE1","title":"Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-08-17","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":30},{"nctId":"NCT05897554","phase":"NA","title":"Intra-arterial Thrombolysis After Successful Thrombectomy for Acute Ischemic Stroke in the Posterior Circulation (IAT-TOP)","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-08-11","conditions":"Acute Ischemic Stroke, Arterial Thrombosis, Posterior Circulation Brain Infarction","enrollment":247},{"nctId":"NCT06453876","phase":"PHASE3","title":"Percutaneous Embolectomy, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism","status":"NOT_YET_RECRUITING","sponsor":"Jesper Kjaergaard","startDate":"2025-06-01","conditions":"Pulmonary Embolism","enrollment":210},{"nctId":"NCT06571149","phase":"PHASE4","title":"Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-03-14","conditions":"Ischemic Stroke","enrollment":906},{"nctId":"NCT05429476","phase":"PHASE3","title":"EXtending the Time Window for Thrombolysis in Posterior Circulation Stroke Without Early CT Signs","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-08-17","conditions":"Stroke, Acute Ischemic","enrollment":234},{"nctId":"NCT03581877","phase":"PHASE4","title":"Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwell Health","startDate":"2019-01-28","conditions":"Pulmonary Embolism, Pulmonary Hypertension, Thromboembolism","enrollment":31},{"nctId":"NCT02157532","phase":"NA","title":"Endovascular Acute Stroke Intervention Trial - the EASI Trial","status":"SUSPENDED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2013-01","conditions":"Stroke, Acute","enrollment":480},{"nctId":"NCT06556446","phase":"","title":"Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2024-01-01","conditions":"Ischemic Stroke","enrollment":2800},{"nctId":"NCT06433011","phase":"NA","title":"The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary Embolism","status":"NOT_YET_RECRUITING","sponsor":"Thrombolex, Inc.","startDate":"2024-06-25","conditions":"Pulmonary Embolism","enrollment":500},{"nctId":"NCT05295173","phase":"PHASE3","title":"A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE）","status":"COMPLETED","sponsor":"Angde Biotech Pharmaceutical Co., Ltd.","startDate":"2022-03-21","conditions":"Acute Ischemic Stroke","enrollment":1412},{"nctId":"NCT06234813","phase":"NA","title":"Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro Study","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2023-04-06","conditions":"Glanzmann Thrombasthenia","enrollment":20},{"nctId":"NCT06120179","phase":"NA","title":"The RESCUE II Study. The Bashir™ Endovascular Catheter (BEC),","status":"UNKNOWN","sponsor":"Temple University","startDate":"2023-11","conditions":"Acute Submassive Pulmonary Embolism","enrollment":20},{"nctId":"NCT04248868","phase":"PHASE3","title":"tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden","status":"COMPLETED","sponsor":"Thrombolex, Inc.","startDate":"2020-06-23","conditions":"Pulmonary Embolism","enrollment":109},{"nctId":"NCT03927508","phase":"PHASE1","title":"First - In - Man Study to Assess the Safety and Feasibility of The Bashir™ Endovascular Catheter for the Treatment of Acute Pulmonary Embolism","status":"COMPLETED","sponsor":"Thrombolex, Inc.","startDate":"2019-03-14","conditions":"Pulmonary Embolism","enrollment":9},{"nctId":"NCT03661411","phase":"PHASE4","title":"Antiplatelet vs R-tPA for Acute Mild Ischemic Stroke","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2018-10-17","conditions":"Stroke","enrollment":760},{"nctId":"NCT03740958","phase":"PHASE4","title":"Argatroban Plus R-tPA for Acute Ischemic Stroke","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2018-12-21","conditions":"Stroke","enrollment":808},{"nctId":"NCT02396758","phase":"PHASE4","title":"Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2015-06-12","conditions":"Pulmonary Embolism and Thrombosis","enrollment":131},{"nctId":"NCT01513759","phase":"PHASE3","title":"Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2012-06-07","conditions":"Pulmonary Embolism, Acute Pulmonary Embolism, Sub-massive Pulmonary Embolism","enrollment":150},{"nctId":"NCT04028518","phase":"PHASE2","title":"A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke.","status":"UNKNOWN","sponsor":"Angde Biotech Pharmaceutical Co., Ltd.","startDate":"2019-07-20","conditions":"Acute Ischemic Stroke","enrollment":180},{"nctId":"NCT03506009","phase":"PHASE4","title":"Argatroban Plus r-tPA for Posterior Circulation Infarction（AR-PCI）","status":"TERMINATED","sponsor":"Hui-Sheng Chen","startDate":"2018-07-11","conditions":"Argatroban, Rt-PA","enrollment":3},{"nctId":"NCT01580839","phase":"PHASE3","title":"EXTEND (International): Extending the Time for Thrombolysis in Emergency Neurological Deficits (International)","status":"COMPLETED","sponsor":"Neuroscience Trials Australia","startDate":"2012-12-06","conditions":"Stroke","enrollment":45},{"nctId":"NCT00887328","phase":"PHASE3","title":"Extending the Time for Thrombolysis in Emergency Neurological Deficits","status":"COMPLETED","sponsor":"Neuroscience Trials Australia","startDate":"2010-06","conditions":"Stroke","enrollment":180},{"nctId":"NCT02886390","phase":"NA","title":"r-tPA Thrombolytic Therapy in Combination With Remote Ischemic Conditioning for Acute Ischemic Stroke Recovery","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2018-06-16","conditions":"Stroke, Acute","enrollment":60},{"nctId":"NCT00265005","phase":"PHASE1","title":"Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants","status":"TERMINATED","sponsor":"University of Louisville","startDate":"2005-06","conditions":"Thrombosis","enrollment":12},{"nctId":"NCT03231384","phase":"NA","title":"Rt-PA Thrombolytic Therapy in Combination With Remote Ischemic Conditioning for Acute Ischemic Stroke","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2017-08-10","conditions":"Ischemic Stroke","enrollment":31},{"nctId":"NCT02974283","phase":"NA","title":"Protective Effects of Normobaric Hyperoxia on Blood Brain Barrier in Patients With Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Capital Medical University","startDate":"2016-12","conditions":"Stroke, Acute","enrollment":40},{"nctId":"NCT02347358","phase":"PHASE2","title":"Mechanical Opening Device Implantation Following Intravenous r-tPA for Recanalization in Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"The Second Artillery General Hospital","startDate":"2015-02","conditions":"Ischemic Cerebrovascular Accident","enrollment":100},{"nctId":"NCT00082355","phase":"PHASE2","title":"Low-Dose Alteplase to Treat Blood Clots in Deep Leg Veins","status":"COMPLETED","sponsor":"Richard Chang, M.D.","startDate":"2004-05","conditions":"Acute Deep Venous Thrombosis of the Lower Extremity","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":392,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"r-tPA","genericName":"r-tPA","companyName":"Thrombolex, Inc.","companyId":"thrombolex-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R-tPA is a small molecule that acts as a serine protease to convert plasminogen into its active form plasmin, facilitating the breakdown of blood clots. It is used to treat conditions such as acute stroke and acute pulmonary embolism, and is administered as part of the standard treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}